Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics And Schering-Plough Extend Collaboration


WALTHAM, Mass.--Genome Therapeutics here announced the extension of its $43.5 million collaboration with Schering-Plough to identify and develop novel antiinfectives for drug-resistant bacteria. The expanded agreement will carry the alliance at least through March 31, 2000. The two companies also forged a $67 million alliance in December, 1996, to develop novel therapeutics for asthma, and a $33 million antifungal collaboration in September, 1997.

Genome Therapeutics' commercial gene discovery strategy is to identify and characterize human genes associated with major diseases and to elucidate bacterial genes responsible for many serious infectious diseases.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.